Primary central nervous system lymphoma

Primary central nervous system lymphoma (PCNSL) is a diffuse large B cell lymphoma in which the brain, spinal cord, leptomeninges and/or eyes are exclusive sites of disease. Pathophysiology is incompletely understood, although a central role seems to comprise immunoglobulins binding to self-proteins expressed in the central nervous system (CNS) and alterations of genes involved in B cell receptor, Toll-like receptor and NF-kappa B signalling. Other factors such as T cells, macrophages or microglia, endothelial cells, chemokines, and interleukins, probably also have important roles. Clinical presentation varies depending on the involved regions of the CNS. Standard of care includes methotrexate-based polychemotherapy followed by age-tailored thiotepa-based conditioned autologous stem cell transplantation and, in patients unsuitable for such treatment, consolidation with whole-brain radiotherapy or single-drug maintenance. Personalized treatment, primary radiotherapy and only supportive care should be considered in unfit, frail patients. Despite available treatments, 15-25% of patients do not respond to chemotherapy and 25-50% relapse after initial response. Relapse rates are higher in older patients, although the prognosis of patients experiencing relapse is poor independent of age. Further research is needed to identify diagnostic biomarkers, treatments with higher efficacy and less neurotoxicity, strategies to improve the penetration of drugs into the CNS, and roles of other therapies such as immunotherapies and adoptive cell therapies. This Primer summarizes the epidemiology, pathophysiology, diagnosis and treatment of primary central nervous system lymphoma. This Primer also reviews future research avenues and the effect that this disorder has on the quality of life of patients.

Automated summary

Primary central nervous system lymphoma (PCNSL) is a diffuse large B cell lymphoma that primarily affects the brain, spinal cord, leptomeninges, and/or eyes. The pathophysiology is not fully understood, but it involves interactions between immunoglobulins, genes, and various cells and molecules in the central nervous system (CNS). The standard treatment usually involves chemotherapy followed by stem cell transplantation, with radiotherapy as an option for some patients. However, treatment response and relapse rates remain challenging, necessitating further research for better diagnostic biomarkers, improved therapies, and understanding of the disease's impact on patients' quality of life.